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1 ABSTRACT 
Crohn’s disease (CD) is a chronic condition which affects to the immune system . It can affect to 
any part of the digestive tract and be associated with external manifestations. The causes of the 
disease remain unknown, although it seems to be the result of a combination of factors, such as 
genetic predisposition, environment, lifestyle and the composition of the microbiota, among 
others. The treatment protocol begins with a change in eating and smoking habits, and is 
continued with different lines of treatment, including corticosteroids, immunomodulators, and 
biologic therapy (infliximab and adalimumab), which have shown differences in response among 
patients, especially with biologic treatment. Several studies have considered the possibility that 
these differences in response are caused by the genetic variability of patients. Many genes have 
been investigated as potential predictors of response to biological drugs such as ADAM17, 
ATG16L1, EMSY, CASP9, CCNY, CNTN5, FASLG, FCGR, NOD2, PTGER4, IL13, IL1B, IL27, IL11, IL17F, 
TNF, and TNFR genes. In this review, we will gather the information on influence of gene 
polymorphisms investigated to date on response to biological drugs in CD patients. 
2 INTRODUCTION 
Crohn’s disease (CD) is a chronic condition which affects to the immune system . It can affect to 
any part of the digestive tract and be associated with external manifestations. Fistulas and/or 
stenosis are commonly developed, which are explained by the transmural nature and tendency 
to fibrosis of the disease. It is also characterized by cycles of active disease and remission periods 
(1). 
According to a recent study, the incidence is higher in developed industrialized countries, such 
those in Europe and North America, where it reaches values of 12.7 to 20.2/100,000 (2). The 
prevalence is also increased in these countries, reaching values of 322-319/100,000 (2). 
The causes of the disease remain unknown, although it seems to be the result of a combination 
of factors, such as genetic predisposition (mainly abnormalities in genes of the immune system), 
environment and lifestyle (hygiene, diet, sleep, stress, smoking habits...), medication 
(particularly non-steroidal anti-inflammatory drugs), and the composition of the microbiota, 
among others (3,4). Smoking is one of the risk factors associated with CD (OR:1.76; CI95%:1.4-
2.22) (5); even passive smokers have shown increased risk develop this disease (6). Individuals 
from large families who have been breastfed and also exposed to farm animals from an early 
age have shown decreased CD risk, which is directly related to the composition of their 
microbiota (7). Patients with greater diversity in their microbiota are less predisposed to 
inflammatory bowel disease (IBD) and especially to CD. Many other factors such as hygiene, 
infections, antibiotic use have also been associated to CD (8-11). Appendectomy is another 
factor that has been associated with the onset of the disease after 20 years (12). In relation to 
diet, several studies corroborate that a fibre-rich, fat-low diet decreases the risk of CD, whereas 
fat-rich, vitamin D deficient diets are related to the appearance of IBD (13,14). CD family 
antecedents are present in 2-14% of CD patients; furthermore, the risk of IBD after the thirties 
increases in 1 out of 3 individuals when both parents are affected, showing a strong genetic 
influence (8). Among the genetic factors, there are DNA regions related to the immune system 
which have shown a high association with CD (9). A recent study in 75000 patients has identified 
163 risk genes for CD (10). Some of the genes included in these regions are NOD2 (also known 
as CARD15), associated with a 20-40 fold increased risk in homozygous patients, and a 2-4 fold 
increase in heterozygotes (11,12); HLA, ATL16L1, IRGM and SLC11A1 (9,13). Other genes 
involved with the immune response which are associated with the onset of the disease are the 
NF-kB gene (14), interleukin genes IL1, IL6, IL23R (15), and CARD9 (13). Some, but not all of these 
genes have been investigated as potential biomarkers of outcomes in biological therapy for CD. 
In this article, we will review the research studies conducted to date focused on the influence of 
gene polymorphisms on response to biological drugs in CD patients. 
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2.1 PHARMACOTHERAPY OF CROHN’S DISEASE 
The severity of the disease needs to be assessed to define the treatment. The Crohn's disease 
activity index (CDAI) quantifies the inflammatory activity and measures 8 variables, including 7 
clinical and one analytical parameter (16). A greater CDAI score indicates higher severity of the 
disease. The level of C-reactive protein (CRP) is another parameter used to assess the degree of 
the disease activity, since high levels are often associated with CD. 
When CDAI>220 and CRP levels>10 mg/l are reached, it is considered as active disease. 
Remission is established when CDAI is less than 150, and response when CDAI decreases 100 
points from baseline (17). Response to treatment is usually complemented with a questionnaire 
to the patient, the Inflammatory Bowel Disease Questionnaire (IBDQ), to assess their quality of 
life (18). The Harvey-Bradshaw Index (HBI) is a simple index of Crohn’s disease activity also used 
to quantify the symptoms of CD (19). 
The CD treatment guidelines start from changing eating and smoking habits, as they have proven 
to be a factor for the occurrence and recurrence of the disease (15). The treatment protocol is 
then continued with corticosteroids such as prednisone, prednisolone and budesonide, or 
aminosalicylic acid (17). Complementation with immunomodulators (azathioprine and 
mercaptopurine), which are never used as monotherapy, is used when symptoms persist. 
Methotrexate is recommended when there is no response to the above treatments or they are 
contraindicated. When the disease becomes serious, the patient is switched to biological 
therapy with tumour necrosis factor inhibitors (anti-TNF), mainly adalimumab (ADA) and 
infliximab (IFX). And finally, when the disease is recurrent despite treatments, surgery is 
recommended (17). More recently, studies are also being carried out with other biological drugs, 
like cytokine inhibitors such as natalizumab, vedolizumab (20) and ustekinumab (21) for CD 
treatment. Other drugs have also been tested for CD therapy, but with less success, such as 
tofacitinib and abatacept (22,23). The pharmacogenetics of none of the latter has been studied.  
2.1.1 Anti-TNF DRUGS 
The anti-TNF drugs are recombinant human IgG1 antibody proteins, with similar functions but 
differently obtained. ADA is a protein obtained from recombinant DNA in mammalian cells(24), 
whereas IFX is a chimeric protein derived from mice(25). 
2.1.2 Cytokine inhibitors  
Several cytokine inhibitors have been tests in CD patients: 
- Natalizumab: recombinant humanized anti-α4-integrin antibody produced on a murine 
cellular line by recombinant DNA technology (26). 
- Vedolizumab: Humanized monoclonal antibody IgG type that binds to human α4β7 
integrin and is produced in hamster ovary cell (27). 
- Ustekinumab: monoclonal IgGκ anti-interleukin 12/23 human antibody, produced in a 
mouse myeloma cell line using recombinant DNA technology (28). 
3 PHARMACOGENETICS 
Pharmacogenetics studies the influence of variations in the DNA sequence on drug response 
(29). The use of biological drugs (ADA, IFX) as one of the lines of treatment for CD has greatly 
improved the outcomes, but has also showed a great variability in response among patients. 
Several studies have considered the possibility that these differences in response are caused by 
genetic variability of patients (30–33). In this regard, different lines of research carried out in 
recent years have tried to associate variants of ADAM17, ATG16L1, EMSY, CASP9, CCNY, CNTN5, 
Fas Ligand, FCGR, NOD2, NR1I2, PTGER4, IL13, IL1B, IL27, IL11, IL17F, TNF, TRAF3IP2 and TNFR 
genes with the response to treatment with biologics in CD. Some of them, like ATG16L1, NOD2 
Commented [WU1]: https://www.ncbi.nlm.nih.gov/gene/356 
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have also been associated with CD and that prompted the interest in exploring their potential 
role in CD outcomes to biological therapies. 
3.1.1 ADAM17 
ADAM17 is a gene whose transcriptomic product leads to a protein that binds to the membrane 
and displays functions related to cell-cell biological processes and cell-matrix interactions. It is 
also involved in processes of muscle development, neurogenesis and fertilization. Furthermore, 
the proteins of the ADAM family are structurally related to snake venom disintegrins (34,35). 
Several variants in ADAM17 gene (rs2001658, rs12469362, rs883399, rs1048610, rs2276338, 
rs1056204, rs10929587, rs1880439, rs10495565, rs4464248, rs11684747, rs10929590) were 
investigated in 222 Caucasian patients treated with IFX, including luminal and fistulizing cases 
(33). Remission was considered if CDAI was below 150 at week 4 for patients with luminal CD. 
For patients with fistulizing CD, remission was considered if they had complete absence of fistula 
drainage at week 10. A decrease of 70 points in CDAI from baseline at week 4 was considered 
response in luminal patients, while in fistulizing patients the definition of response was a 
decrease of 50% of the fistula drainage at two consecutive visits at week 10. Changes in CRP 
levels were evaluated at weeks 0, 4, 8 and 12. No association of the different haplotypes with 
remission or response to IFX was shown. However, the rs2001658TT, rs12469362CC, 
rs883399GG, rs1048610CC, rs2276338CC, rs1056204CC, rs10929587TT, rs10495565GG, 
rs4464248AA, rs11684747AA haplotype was significantly less frequent in the clinical non-
responders (p=0.0027) (Table 1). Interestingly, all homozygous patients for this haplotype (n=16) 
presented clinical response according to a CDAI and also biological response according to CRP 
(40%relative reduction). The haplotype composed by rs12469362C, rs1056204C, rs10495565G 
and rs4464248A in homozygosis was significantly associated with response to IFX (nonadjusted 
P<0.002). 
3.1.2  ATG16L1 
The ATG16L1 gene is located on chromosome 2 and encodes a protein related to autophagy 
processes. It has been observed that defects in this gene can cause susceptibility to 
inflammatory bowel disease (36). 
In order to investigate the influence on response to ADA of different single gene polymorphisms 
(SNP) associated to CD risk, 33 SNP in 31 genes were sequenced in 102 Slovak patients with CD 
(37). NOD2, IL23R, SLC22A5, SLC22A4, CTLA4, PTGER4, CASP9, IL27, EMSY, CCNY, IL13, NR1I2 
were among the genes studied. Response was measured using the IBDQ and CRP levels at 4, 12, 
20 and 30 weeks. The T-allele of the rs10210302 variant of the ATG16L gene showed the 
strongest association with response at 12 weeks (OR: 9.44, CI95%: 2.49- 35.83, pc=0.027, 
p=8.11·10-4), and was maintained after 20 weeks (p=4.5·10-3) (Table 1 and 2). Patients carrying 
the T-allele also showed higher variation in CRP levels after 12 weeks (pc=0.059, p=1.79·10-3) 
and 20 weeks (p=7.6·10-3). Furthermore, patients with the TT genotype maintained the good 
response to ADA, according to IBDQ after 20 (p=4.61·10-02) and 30 weeks of treatment 
(p=4.93·10-02) (Tabla 2).  
3.1.3 EMSY  
This gene is also known as C11orf30, is located on chromosome 11 and its N-terminal domain is 
related to the BRCA2 protein, silencing the gene activation (38). 
The CC genotype of the rs7927894 variant was associated with lower levels of CPR and a better 
IBDQ score in 102 Slovak patients with CD (37). In particular, the difference between the ADA 
response in CC patients was even greater at week 20, compared with those carrying the T allele 
(p=5.83·10-03, pc=0.192) (Table 2). 
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3.1.4 CASP9 
CASP9 gene, located on chromosome 1, encodes the caspase 9 protein, involved in the apoptosis 
signalling pathway. It belongs to the family of cysteine-aspartic proteases. CASP9 protein can be 
proteolysed and activated by the action of the apoptosome (39,40). 
The influence of several apoptosis-related genes (FASLG, FAS, TNFRSF10A, CASP3, CASP9, BAD, 
BCL2, BIRC5, MMP1, MMP3) on response to treatment was investigated in 287 CD patients (204 
luminal/83 fistulizing) treated with IFX complemented with immunomodulators 
(azathioprine/mercaptopurine) (31). Total response was considered when CDAI reached a score 
of 150 or a decline of 70 points compared to initial CDAI; luminal CD response was measured 
after 4 weeks and fistulizing CD at week 10. The rs4645983 variant in CASP9 was associated to 
response only in patients with luminal CD (Table 1). Specifically, the TT genotype was associated 
with a better response (OR: 1.50, CI95%: 1.34-1.68, p=0.044). The good effect of the TT genotype 
on response to anti-TNF drugs was also recently shown in 102 CD Slovak patients treated with 
ADA  (Table 2) (37). In fact, all responders at week 12 presented the TT genotype. However, this 
effect became non-significant after Bonferroni correction. 
3.1.5 CCNY 
This gene is known as cyclin Y and encodes a protein which regulates cell cycle and different 
transcription factors. One of their main functions is to activate the promoter of v-myc avian 
myelocytomatosis viral oncogene homolog (MYC) proto-oncogene, which promotes cell cycle 
progression and takes part in apoptosis and cellular transformation (41). 
A recent study showed better response in patients carrying the CC-genotype of the rs12777960 
variant of the CCNY gene in 102 Slovak CD patients treated with ADA for 4 weeks (OR:3.26, 
CI95%: 1.27- 8.38, p=1.56·10-02, pc=0.515). An improvement in CRP levels was also showed after 
12 and 20 weeks (p=6.78·10-3, pc=0.224) (Table 2) (37). 
3.1.6 CNTN5 
The CNTN5 gene is located on chromosome 11 and encodes a cell adhesion molecule (contactin 
5), a member of the immunoglobulin superfamily, which mediates cell surface interactions 
during nervous system development. Alternative names for this gene are NB-2 and HNB-2s (42). 
Gene polymorphisms rs1568885, rs1813443, and rs4411591 in CNTN5 have been recently 
investigated in a cohort of 126 Greek CD patients treated with IFX (43). Remission was 
established according to HBI, CRP levels and ileocolonoscopy at weeks 0, 12 and 20. The T-allele 
of rs1568885 variant was associated to lower response rate (TT: ORmoderate/good: 8.14, CI95%: 1.35-
49.05, p=0.024; AT: OR:2.71, CI95%: 1.11-6.64, p=0.035; TT: ORnon-responder/good:21.37, CI95%: 2.73-
167.2, p=0.007/ AT: OR: 4.75, CI95%: 1.26-17.9, p=0.032) (Table 1). The CC-genotype of the 
rs1813443 polymorphism was associated to poor response (ORmoderate/good: 6.13, CI95%: 1.74-
21.63, p=0.005) and to non-response to IFX (ORnon-responder/good:11.5, CI95%: 2.5-52.84, p=0.002). 
The rs4411591 variant did not showed association to drug response. 
3.1.7 FASLG 
FASLG, located on chromosome 1, encodes the Fas ligand, a transmembrane protein which binds 
the FAS receptor to induce apoptosis. Its function is closely related to the regulation of the 
immune system (44,45). 
Twenty-one gene polymorphisms in several genes involved in the apoptotic process (FASLG, FAS, 
TNFRSF10A, CASP3, CASP9, BAD, BCLXI, API4, MMP1, MMP3) were investigated in a cohort of 
287 CD patients treated with IFX (204 refractory luminal and 83 fistulizing) (31). Total response 
was considered for patients with CDAI score of 150 or a decrease of 70 units from the baseline 
value, and was evaluated at 4 weeks for luminal patients and at 10 weeks for fistulising cases. 
Remission in fistulising patients was defined as disappearance of open fistulas, and moderate 
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response when open fistules drainage had reduced less than 50%. The C-alelle of the rs763110 
variant of the FASLG gene was associated to better response to IFX in both luminal and fistulising 
patients (luminal: OR:0.11, CI95%:0.08-0.56, p=0.002; fistulising: OR:1.66, CI95%: 1.21-2.29, 
p=0.02) (Table 1). However, the C-allele has also been associated to a higher risk of 
hypersensitivity reactions to IFX in 126 CD patients (OR: 4.0, CI95%: 1.1-22.4, p=0.041) (46). This 
study also investigated the effect of rs75622480 and rs5030772 polymorphisms in FASLG, failing 
to find any association to response to IFX. 
3.1.8 FCGR3A 
FCGR3A gene, also known as FCγRIIIA, encodes a protein related to the immune system, 
specifically with the antibody dependent response (47). It is located on chromosome 1 and has 
different variants. Specifically, the T>G substitution at rs396991 (F158V) gene polymorphism 
corresponds to the change of the aminoacid phenylalanine (F) by valine (V) at position 175 of 
the protein. F presents low affinity for IgG, whereas V shows high affinity (48). 
The high affinity variant (VV) of the F158V polymorphism was associated with a better response 
to IFX in a cohort of 344 CD patients (Table 1) (49). Patients with baseline CRP values within the 
two highest quartiles (n=156) carrying the VV genotype showed a trend toward a greater relative 
change in CRP at week 6 (p=0.085, one-tailed p=0.043). This effect of the VV genotype on CRP 
improvement was further confirmed in a cohort of 102 Japanese CD patients (Table 1) (50). 
Response was evaluated according to CDAI and CPR levels at 8 and 30 weeks. The VV genotype 
was associated to CPR improvement at week 8 (p=0.044), but the effect was not significant after 
30 weeks. This study also investigated the potential influence of other polymorphisms in FCGR3A 
gene (FCGR3A-159, FCGR3A-160), but no associations were found (50).  
Other studies with smaller samples (106 and 189 patients) have failed to find an effect of F158V 
variant on response to IFX in CD patients  (51,52).  
3.1.9 NOD2 
The NOD2 gene encodes the caspase recruitment domain-containing protein 15 (CARD15) or 
inflammatory bowel disease protein 1 (IBD1). Its main function is to activate NFKB protein in 
bacterial infections, by recognizing the muramyl dipeptide moiety (53,54). It has also been 
related to CD susceptibility(55). 
The association of NOD2 variants (rs2066844 or R702W, rs2066845 or G908R and rs2066847 
L1007Profs) with relapse after IFX treatment was investigated in 14 CD patients, with no effect 
observed (56). In consonance with this, these variants did not influence response to ADA either 
in 102 Slovak CD patients treated (according to IBDQ and CRP levels measured at  4, 12, 20 and 
30 weeks) (37) or 16 CD patients (evaluated by CDAI after 52 weeks) (57). Remission after IFX 
treatment was not associated either to NOD2 polymorphisms (G881R, G908R, R675W, R702W, 
980fs, 3020insC) in 534 patients with active CD (Table 1 and 2) (58). 
3.1.10 NR1I2 
The NR1I2 gene is located in chromosome 3 and encodes a protein which belongs to the 
superfamily of nuclear receptors, whose main function is to bind response elements, as receptor 
X retinone (RXR), to regulate CYP3A4 transcription (59,60). The GG genotype in rs3814057 
polymorphism of NR12 gene showed a trend to good long-term response to ADA (p=9.64·10-3, 
pcorr=0.318) in 102 Slovak CD patients, but the statistical significance was lost after multiple 
comparison correction (Table 2) (37). 
3.1.11 PTGER4 
PTGER4 gene, located in chromosome 5, encodes a prostaglandin receptor which belongs to the 
G-protein coupled receptor family and is one of four receptors identified for prostaglandin E2. 
It acts by activating signalling factors of T cells (61). 
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The GG genotype of the PTGER4 rs10512734 variant has showed a trend to short-term response 
in 102 Slovak CD patients (week 12:  p=4.62·10-3, pcorr=0.152) (Table 2) (37). 
3.1.12 TRAF3IP2 
Located in the chromosome 6, the protein encoded by this gene is involved in the process of 
regulating the immune system in response to pathogens, inflammatory and stress signals. 
Specifically, it regulates cytokine response to ReI/NF-kappaB transcription factors (62,63).   
The association of several variants of this gene (rs10872070, rs6941014, rs1883136, rs1040383, 
rs9374263, rs2075966) with response to IFX was studied in 113 Japanese CD patients. Only the 
rs183136 polymorphism was associated with response to IFX after 1 year of treatment, showing 
a lower frequency of the AA genotype (recessive model) in responders (ORC/AA: 0.213, CI95%: 
0.053-0.860, p=0.041)(Table 1)(64). 
3.1.13 IL11 
The protein encoding this gene is interleukin 11, whose main function is to stimulate the 
development of T cell dependent immunoglobulin produced by B lymphocytes. It belongs to the 
gp130 family of cytokines, with the role of assembling the receptors subunits contained in the 
IL6ST transmembrane signalling molecule (gp130) (65). 
The influence of rs116760 and rs1042506 polymorphisms in IL11 gene on response to IFX were 
investigated in 350 patients (Table 3) (66). Response criteria were established as HBI<4 for 
luminal CD and 100% fistulae healing for fistulising CD patients; partial responders were defined 
as HBI<3 and >50% reduction in fistulae, respectively. The rs1126760_C y rs1042506_T 
haplotype was associated with better response to IFX (OR: 1.72, 95%CI: 0.91-3.21, p=0.068) (66). 
3.1.14  IL13 
IL13 gene is located in chromosome 5, and encodes a cytokine mainly involved in immune 
processes. Its transcription is activated by Th2 cells, and leads to the activation of IgG4 and IgE 
synthesis in B cells (67). 
The AA genotype of the rs1295686 variant of IL13 gene was associated to long-term response 
(over week 20) to ADA (Table 2), according to IBDQ values in 102 Slovak CD patients (p=6.07·10-
3, pc=0.2) (37). Patients with AA genotype improved IBDQ at week 30 compared to patients with 
the G allele (p=1.84·10-2, pc=0.607).  
3.1.15 IL27 
The IL27 gene is located on chromosome 16 and encodes one of the subunits of a heterodimeric 
cytokine which participates in protection against virus, by promoting proliferation of naive CD4+ 
T cells (68). 
The rs8049439 variant of IL27 gene was found to be associated with response to ADA after 4 
weeks, according to IBDQ and CRP in 102 CD patients. The T-allele was more frequent among 
responders, compared with the CC genotype (OR: 9.67, CI95%: 1.65, 56.22, p=9.71-10-3, 
pc=0.320); increased CRP was higher in patients with TT genotype compared to CC patients 
(p=1.61·10-2, pc=0.531). Regarding IBDQ, the T-allele also presented a trend to better response 
(p=2.96·10-02, pc=0.977) (Table 2) (37). 
3.1.16 IL17F 
IL17F gene is located on chromosome 6, and its protein product is involved in the defence 
against pathogens, since it is expressed in the mucosa and epithelial barrier. It is also expressed 
in CD4+ T lymphocytes and monocytes activated, and works as a recruiter of leukocytes 
(neutrophils), promoting granulopoiesis and inducing inflammation by activating cytokines like 
IL6, IL8, IL2 and GSF2/GM_CSF (69,70). 
Commented [ta5]: or 
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The association of different variants of this gene (rs763780, rs766748, rs12201582, rs9382084, 
rs722323, rs1266828, rs2294934) with response was studied in 113 Japanese CD patients 
treated with IFX (Table 3). Response was defined as decrease in CDAI less than 150, while no 
changes in CDAI or exacerbation of disease activity was categorized as non-response. Among 
the different polymorphisms studied, only rs766748 was associated with response after a year 
of treatment. In particular, the dominant model for the A-allele was less frequent among 
responders (OR:0.203, p=0.019) (64). This study also included different polymorphisms of genes 
related to IL17 as were IL17A (rs4711998, rs8193036, rs3819024, rs2275913, rs3819025), IL17RA 
(rs2270241, rs2241042, rs5748863, rs5748864, rs2241049, rs2229151, rs2895332), IL17R 
(rs7627880, rs279545). None of these polymorphisms showed association with response to IFX. 
3.1.17 TNF/TNFR 
The main function of the tumour necrosis factor (TFN) gene is to promote immune response and 
processes involved in inflammation, differentiation, proliferation, apoptosis and coagulation. It 
is located in chromosome 6. The superfamily of TNF receptors (TNFRSF10A, TNFR1, TNFR2 and 
TNFRSF1B), important for the proper functioning of the immune system, are also related with 
this gene (71). Mutations in these genes are strongly related with autoimmune diseases  
(32,72,73). 
The extensive study of TNF gene has yielded many polymorphisms potentially associated to 
response to biological therapy in CD patients, among them rs1799724, rs1799964, rs1800629, 
and rs361520 (Table 4). 
3.1.17.1 TNF -238 
The variant in position -238 of the promoter region of the TNF gene (rs361525) did not show 
influence on response to IFX in 106 Greek CD patients after 20 weeks (51). Song et al. recently 
investigated the influence of several TNF gene polymorphisms on response to biological therapy, 
especially anti-TNF, in patients with different autoimmune diseases (psoriasis, ankylosing 
spondylitis and CD) in a meta-analysis which included 16 studies (including 7 in CD patients) and 
983 (452 with CD) patients (72). The G variant was associated to good response to treatment in 
the overall population (OR:2.208, CI95%:1.197-4.074, p=0.011), particularly for Caucasian 
patients (OR:2.196, CI95%:1.161-4.154). However, the stratification by disease did not show 
association of this polymorphism with response. 
3.1.17.2 TNF -308 
A study with 23 CD patients treated with IFX showed a high number of A carriers of the TNF -308 
(rs1800629) variant in the nonresponding group (74). The influence of this SNP on response to 
anti-TNF was also investigated in the recent meta-analysis  by Song et al., showing the 
rs1800629G variant was associated to response in the overall population with different 
autoimmune diseases (OR:1.388, CI95%: 1.388-2.150, p=0.000012) and in Caucasians (OR:2.005, 
CI95%: 1.417-2.38, p=0.000086), but not Asians. This effect was also evident in the 496 CD 
patients (OR:1.508, CI95%: 0.973-2.338, p=0.066) from 8 studies and in spondylitis patients (72). 
3.1.17.3 TNF -857 
The -857 variant (rs1799724), located in the promoter region of TNF gene, was also investigated 
in the recent meta-analysis by Song et al. (72). The C-allele was associated with good response 
to anti-TNF in the overall population (OR:1.889, CI95%: 1.245-2.866, p=0.003), particularly in 
Caucasian patients (OR:1.779, CI95%: 1.319-3.790, p=0.03). The stratification by disease failed 
to confirm this association individually.  
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3.1.17.4 TNFRSF1A 
The TNFRSF1A, also known as TNFR1, located in chromosome 12, encodes the 1A member from 
the TNF superfamily of receptors. It is activated after NF-Κβ binding, promoting apoptosis 
(75,76). 
A recent study has investigated the role of two polymorphisms in TNFRSF1A (rs767455 and 
rs4149570) on response to IFX in 80 CD patients, according to HBI index (32). The rs4149570 
polymorphism did not show any influence on response to IFX, but patients carrying the G-alelle 
of rs767455 variant experienced reduced effectiveness of IFX, compared to AA patients 
(OR:0.37, CI95%: 0.11-0.82), and this association remained after adjust by clinical and 
sociodemographic variables, such as age, sex, disease location and life-style (OR:0.26, CI95%: 
0.08-0.9). In consonance with this, a recent meta-analysis in autoimmune diseases (including 2 
studies compiling 377 CD patients) has found a trend of the A-allele to better response to anti-
TNF therapy (Table 4)(73). 
The G-allele of the A36G (Pro12Pro) variant has been associated with lower response to IFX in 
344 CD patients, defined as CDAI decrease to 70 points or normalized CDAI in 150 points (OR: 
0.47, CI95%:0.234-0.946, p=0.0343), although biological response (CRP) was not associated 
(Table 4) (77). 
Other polymorphisms in TNFRSF1A (rs4149584, rs4149570, and rs4149569) have showed no 
effect on response or adverse reactions in 126 CD patients treated with IFX (Table 4) (46). 
3.1.17.5 TNFRSF1B 
The TNFRSF1B, also known as TNFR2, is located in chromosome 1, encodes the 1b member from 
the TNF superfamily of receptors, whose function is to recruit anti-apoptotic proteins c-IAP1 and 
c-IAP2 (75). 
The rs1061624A/rs3397T haplotype has been associated with worse response to IFX, according 
to HBI index, in 297 Spanish CD patients (OR:1.78, C95%: 1.09-2.9, p=0.015)(78) and 80 Japanese 
CD patients (p=0.01)(32). In the Spanish study, the rs1061624A variant was also more frequent 
in non-responders (OR:1.63, CI95%:1.05-2.51, p=0.02), and the CC-genotype of the rs3397 
variant was associated with better response rates (OR:3.19, CI95%:0.95-16.78, p=0.05) (Table 4) 
(78). 
The effect of three variants in TNFRSF1B gene (rs976881, rs1061622, rs652625) on response to 
IFX after 12 weeks, measured according to HBI index, was evaluated in 126 CD patients (46). The 
T-allele of the rs652625 variant was related to a decreased risk of adverse reactions to IFX 
(OR:0.2, p=0.043), whereas the GG genotype of rs976881 variant and the G-allele of rs1061622 
polymorphism were associated to better response (OR:3.3, CI95%:1.2-9.1, p=0.014; OR:5.5, 
CI95%:1.5-25.5, p=0.007, respectively) (46). Although other studies have not found the 
rs1061622 variant associated with response (32), the good effect of rs1061622G allele of 
TNFRSF1B gene has been recently confirmed in a meta-analysis including 1062 patients (377 
with CD) from 8 studies in different autoimmune diseases (psoriasis, rheumatoid arthritis and 
CD), showing the T-allele associated to no response in the overall population (OR:0.72, CI95%: 
0.57-0.93, p=0.08)(73). The stratification by disease only confirmed the effect on rheumatoid 
arthritis and psoriasis, but not in CD, probably due only 2 studies were included. The rs1061624 
polymorphism was associated with worse/absence of response in the heterozygote (AG vs GG: 
OR: 2.54, 95%CI:1.30-4.96, p=0.007) and dominant models (AA/AG vs GG: OR: 2.07, 95%CI: 1.10-
3.93, p=0.025) in the meta-analysis (73). The rs3397 was also associated with non-response in 
the heterozygote model (ORCT vs TT: 1.17, 95%CI:0.68-2.02, p=0.026). These associations were lost 
after stratification by disease. The rs1061622 (T587G) polymorphism in the TNFRSF1B gene did 
not show any influence on response to IFX in 344 CD patients, according to CDAI improvement 
and CPR levels (Table 4)  (77). 
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3.1.17.6 TNFAIP6 
TheTNFAIP6 gene encodes a protein involved in the stability of the extracellular matrix and cell 
migration. Proteins which develop this type of function are characterized by secreting properties 
and present a hyaluron binding domain (79–81). 
The association of different variants of this gene (rs11677200, rs2342910, rs3755480, 
rs10432475) with response to IFX was studied in 350 CD patients (66). The rs11677200_C/ 
rs2342910_A/ rs3755480A/ rs10432475A haplotype showed a trend to better response to IFX 
(OR: 0.71; 95%CI: 0.46-1.09; p=0.10) (Table 4). 
3.1.18 Other genes 
During the last decade, the influence of other genes on response to biological therapy in patients 
with CD has also been investigated, although with poor results. Some of these genes are CD14, 
TLRA, MDR1, ABCG2, LTA, CRP, mainly related to the immune response or the onset of the 
disease. Genes related with calcium canals like S100A9, S100A12, S100A8, and surviving 
promoters have also been investigated. No influence of any of these genes was found with 
response to treatment in CD.  
In some studies, the small sample size may have provoked the lack of association. CD14 
(rs2569190) and TLRA (rs4986790) polymorphisms showed no effect on response to IFX or ADA 
in 24 Spanish CD patients after 52 weeks (57). ABCB1 (rs2032582 and rs1045642) and ABCG2 
(rs2231137 and rs1131142) polymorphisms were investigated in 47 CD patients treated with 
IFX, but no significant associations with response were observed. The IBD5 locus includes the 
IGR variants IGR2060a_1G>C (rs20522057) and IGR3081a_1T>G (82), whose potential 
association with remission (CDAI<150) vs relapses after IFX discontinuation was investigated in 
14 CD patients (56). Relapse after treatment was defined as loss of IFX-induced remission 
(CDAI>220), or evidence of active CD in patients who discontinued IFX. No association was 
found, probably due to the small size of the sample. The predictive value of the IL1B rs1143634 
variant in IFX response was investigated in 29 CD and 18 ulcerative colitis patients. CRP and ESR 
levels were estimated after 3, 6 and 12 months. Response was considered when the 
improvement in CDAI was over 70 points, compared to baseline (Table 3) (83). In this case, 
despite of the small size sample, the C-allele was associated to poorer clinical remission after 14 
weeks of treatment (p=0.027) and also showed a trend to worse response (p=0.051). 
Several LTA gene polymorphisms (rs909253, rs2857713, rs5875327, rs1041981, rs746868, 
3093543) were investigated in a group of 264 patients with CD treated with IFX for 12 weeks 
(84). No association with response to IFX was found, not even after considering the potential 
influence of combined haplotypes. 
Like in the above examples, the association of different polymorphisms  in CRP gene (-717G/A, 
+1444C/T, 4A/G) with the response to treatment IFX (CDAI, CRP) could not be demonstrated in 
189 CD patients(52).  
Several variants in genes related to calcium channels, like S100A9 (rs11205276, rs30141866), 
S100A12(rs724781), S100A8 (rs3006488) were investigated as possible predictors of response 
to IFX in 350 CD patients (66). The S100A9 (rs11205276_G, rs3014866_C) and S100A8 
(rs724781_C, rs3006488_A) haplotypes were associated with non-response (OR: 1.54, 95%CI: 
0.97, 2.43; p=0.05). The same study also explored the influence of polymorphisms in the G0S2 
gene (rs4844486, rs2342910, rs3755480, rs10432475), which showed a trend to worse response 
in patients carrying the rs4844486_A/rs14733683_T haplotype (OR: 0.15; 95%CI: 0.45,15.23; 
p=0.15) (66). 
Polymorphisms in surviving promoters (-625 G/C, -241 T/C, -31 C/T) have been investigated in 
a cohort of 97 Greek CD patients, but no influence on IFX was observed (85). 
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Other genes involved in apoptosis (BAD, BCLXI, API4, MMP1, MMP3) were investigated in 287 
CD patients treated with IFX, but none of them showed association with response (86). 
4 CONCLUSIONS 
In the past decades, a great effort has been done to find pharmacogenetic biomarkers capable 
to predict the response to biologic therapy in CD patients. Many genes have been explored, and 
despite some polymorphisms emerged with a great potential, particularly in members of the 
TNF family, the overall results are poor and no good predictive biomarkers for IFX or ADA 
response have been established. Although some of these biomarkers have showed influence on 
response to biologic therapy in other inflammatory diseases, their effect in CD patients is not 
clearly demonstrated. The cause of this lack of association may be the small size of the studies 
undertaken, even the meta-analyses, and the few studies available for each gene. Therefore, a 
more thorough investigation of the pharmacogenetics of CD therapy is still needed, employing 
more comprehensive sets of genes or even large-scale unbiased studies, in large cohorts of 
patients, as a better approach to identify better biomarkers for CD pharmacotherapy. 
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